Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
The CLEAR LABELS Act would require drug manufacturers to display detailed supply chain information on all prescription and over-the-counter drug labels and packaging. Specifically, drugs would need to show the name, location, and unique facility identifier of the original manufacturer of active pharmaceutical ingredients, the finished drug product manufacturer, and any distributors involved, either directly on the label or through accessible electronic portals like QR codes and barcodes. The bill applies to both finished drug products and active pharmaceutical ingredients used in drugs, and manufacturers must also provide paper copies of this information to anyone who requests them. Drug manufacturers would have at least one year from when the FDA issues final regulations to comply with the new labeling requirements, and the bill includes an exemption from existing customs country-of-origin marking rules for drugs that follow these new labeling standards.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.